Neurocrine Posts $3.29 Q3 Adjusted EPS as Revenue Jumps 41%
NBIX sits 29% above its 52-week low of $122.138.
Summary
Neurocrine reported Q3 adjusted EPS of $3.29, landing alongside the 8-K and 10-Q filed this evening showing revenue of $1.123 billion, up 41%, and net income of $206.5 million. INGREZZA drove $801 million of sales. The adjusted EPS figure is the cleanest read on underlying profitability and comes in as a fresh number beyond the revenue and net income already disclosed. The company also posted 3Q EPS of $1.96. Watch the full-year INGREZZA guidance and the Alvogen ANDA against VYKAT XR disclosed in the 10-Q as the two swing factors for the stock.
At the time of this announcement, NBIX was trading at $157.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $122.14 to $186.12. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.